For the Inventor, By the Inventor

Enter assignee name

Marburg, Germany

Aventis Behring Gmbh

Calculating rank

USPTO Granted Patents = 57

% Expired Patents = 28.1

CIPO Patents = 1

Trademarks = 2

Forward Citations = 1,186

Loading Chart...

Loading Chart...

96 inventors (with patents filed for the assignee):

Jürgen Römisch (10 out of 11 patents)

Alain Fournier (8 out of 27 patents)

Jean-Dominique Guitton (8 out of 13 patents)

4. Patrice Yeh (8 out of 37 patents)

5. Reinhard Fleer (8 out of 21 patents)

6. Annette Feussner (7 out of 18 patents)

7. Gérard Jung (7 out of 15 patents)

8. Juergen Roemisch (6 out of 13 patents)

9. Harald Stauss (6 out of 6 patents)

10. Thomas Weimer (5 out of 28 patents)

11. Hans-Arnold Stoehr (5 out of 12 patents)

12. Gerhard Dickneite (4 out of 29 patents)

13. Hubert Metzner (4 out of 28 patents)

14. Claude Négrier (4 out of 4 patents)

15. Peter Gronski (3 out of 5 patents)

Core Competencies:

Fusion Proteins

Antibodies

Blood Coagulation

Albumin

Erythropoietin

Interferon

Virus Detection

Protein Purification

Therapeutic Agents

Inflammatory Processes

Monoclonal Antibodies

Gene Manipulation

57 patents: Sort by Forward Citations

1. 8197459 - Self-sealing medical fluid transfer device (2012-06-12),

2. 7202021 - Antibodies for specifically detecting pathogenic prions of human origin, and detection methods carried out using these antibodies (2007-04-10),

3. 7153679 - Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis (2006-12-26),

4. 7094577 - Insulin and albumin fusion protein (2006-08-22),

5. 7081354 - Interleukin and albumin fusion protein (2006-07-25),

6. 7056701 - Hormone and albumin fusion protein (2006-06-06),

7. 7041478 - G-CSF and albumin fusion protein (2006-05-09),

8. 6989365 - Methods of treatment with erythropoietin and albumin fusion protein (2006-01-24),

9. 6987006 - Erythropoietin and albumin fusion protein, nucleic acids, and methods thereof (2006-01-17),

10. 6972322 - Interferon and albumin fusion protein (2005-12-06),

11. 6869790 - Preparation of DNA encoding factor XIIIA (2005-03-22),

12. 6831167 - Mutants of the factor VII-activating protease and detection methods using specific antibodies (2004-12-14),

13. 6829875 - Method of venting a filled bottle which is closed by means of an elastic stopper, and apparatus for implementing the method (2004-12-14),

14. 6800461 - Modified factor VIII cDNA (2004-10-05),

15. 6790832 - Pharmaceutical preparation for the treatment of inflammatory processes (2004-09-14),

Company Overview

Aventis Behring GmbH, headquartered in Marburg, Germany, is a leader in biopharmaceutical development, focusing on innovative therapies for serious medical conditions. The company specializes in the research and production of fusion proteins, antibodies, and blood coagulation factors, contributing significantly to advancements in treatment options. Its expertise extends to critical areas such as albumin, erythropoietin, interferon, virus detection, and protein purification, positioning it at the forefront of biopharmaceutical innovation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

57 Patents

#5 in Marburg

#954 in Germany

#12,581 in the World

Marburg, Germany

Aventis Behring Gmbh

Forward Citations = 1,186

96 inventors:

Jürgen Römisch (10 out of 11 patents)

Alain Fournier (8 out of 27 patents)

Jean-Dominique Guitton (8 out of 13 patents)

4. Patrice Yeh (8 out of 37 patents)

5. Reinhard Fleer (8 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aventis Behring Gmbh. Retrieved from https://idiyas.com/company/aventis-behring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…